The acquisition of Tibelia is strategically important I was quite happy to see the announcement of Tibelia by RX. While there wasn't nearly enough financial information to determine the present value impact on Tibelia to RX what it did indicate is the companies desire to spend the accumulated profits (cash) to acquire new products / jurisdictions that will help to grow revenue / profits but more importantly, will help to diversify the companies products as well as add some geographic diversification. I really like to see this.
Add this into the Zofenopril announcement and I believe that RX is on course to begin to show some meaningful revenue growth and increased profitability leading to strong cash flow generation.
I believe that these new products and the growth that they represent, will lead to renewed interest in RX as a higher growth company that should attract more investors and likely result in improving valuation metrics.
I had come close to selling my shares recently, however, I have seen some important changes coming from management that have renewed my interest in the prospects of RX for the short and long-term so I will continue to retain my position in the company.
Keep it up Rene / RX, I like what you are doing.